Effects of deferasirox and deferiprone on cellular iron load in the human hepatoma cell line HepaRG

BioMetals

Volumn 23, Issue 2, 2010, Pages 231-245

  Gaboriau, François ^a   Leray, Anne Marie ^a   Ropert, Martine ^a,b   Gouffier, Lucie ^a   Cannie, Isabelle ^a   Troadec, Marie Bérengére ^a   Loréal, Olivier ^a   Brissot, Pierre ^a,b   Lescoat, Gérard ^a  

^a UNIVERSITÉ DE RENNES 1   (France)

^b PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Cell proliferation; HepaRG cell line; Hepatocytes; Iron chelation; Iron metabolism; Siderophore

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; CALCEIN; CELL PROTEIN; DEFERASIROX; DEFERIPRONE; FERRIC ION; FERRITIN; IRON; IRON CHELATING AGENT; IRON COMPLEX; LACTATE DEHYDROGENASE; SUCCINATE DEHYDROGENASE; TRANSFERRIN RECEPTOR; BENZOIC ACID DERIVATIVE; PYRIDONE DERIVATIVE; TRIAZOLE DERIVATIVE;

ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL LEVEL; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG STRUCTURE; DRUG UPTAKE; ENZYME ACTIVITY; ENZYME RELEASE; FLUORESCENCE ANALYSIS; HEPATOMA CELL; HUMAN; HUMAN CELL; IRON CHELATION; IRON DEPLETION; IRON METABOLISM; IRON STORAGE; IRON TRANSPORT; LIVER CELL; PERLS IRON STAINING; PROTEIN CONTENT; PROTEIN EXPRESSION; STAINING; CHEMICAL STRUCTURE; CHEMISTRY; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; FEMALE; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

BENZOIC ACIDS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FERRITINS; HEPATOCYTES; HUMANS; IRON; IRON CHELATING AGENTS; LIVER NEOPLASMS; MOLECULAR STRUCTURE; PYRIDONES; RECEPTORS, TRANSFERRIN; TRIAZOLES;

EID: 77952488261     PISSN: 09660844     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10534-009-9281-9     Document Type: Article

References (42)

1. Albrecht-Gary A, Crumbliss AL (1998) Coordination chemistry of siderophores: thermodynamics and kinetics of iron chelation and release. Metal Ions Biol Syst 35:239-327
2. Al-Refaie FN, Wonke B, Hoffbrand AV, Wickens DG, Nortey P, Kontoghiorges GJ (1992) Efficacy and possible adverse effects of the oral iron chelator 1, 2-dimethyl-3-hydroxypyrid- 4-one (L1) in thalassemia major. Blood 80:593-599
3. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254
4. Brissot P, Loreal O (2002) Role of non-transferrin-bound iron in the pathogenesis of iron overload and toxicity. Adv Exp Med Biol 509:45-53
5. Brissot P, Wright TL, Ma WL, Weisiger R (1985) Efficient clearance of non-transferrin-bound iron by rat liver. Implications for hepatic iron loading in iron overload states. J Clin Invest 76:1463-1470
6. Brissot P, Troadec MB, Bardou-Jacquet E, Le Lan C, Jouanolle AM, Deugnier Y, Loreal O (2008) Current approach to hemochromatosis. Blood Rev 22(4):195-210
7. Buss JL, Torti FM, Torti SV (2003) The role of iron chelation in cancer therapy. Curr Med Chem 10(12):1021-1034
8. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, Aydinok Y, Kattamis A, Kilinc Y, Porter J et al (2006) A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 107(9):3455-3462
9. Cerec V, Glaise D, Garnier D, Morosan S, Turlin B, Drenou B, Gripon P, Kremsdorf D, Guguen-Guillouzo C, Corlu A (2007) Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor. Hepatology 45(4):957-967
10. Chenoufi N, Huber N, Loréal O, Morel I, Pasdeloup N, Cillard J, Brissot P, Lescoat G (1995) Inhibition of iron toxicity in rat and human hepatocyte cultures by the hydroxypyridin- 4-ones CP20 and CP94. J Hepatol 23:166-173
11. Chenoufi N, Drénou B, Loréal O, Pigeon C, Brissot P, Lescoat G (1998) Antiproliferative effect of deferiprone on the HepG2 cell line. Biochem Pharmacol 56:431-437
12. Collins AF, Fassos FF, Stobie S, Lewis N, Shaw D, Fry M, Templeton DM, McClelland R, Koren G, Olivieri NF (1994) Iron-balance and dose-response studies of the oral iron chelator 1, 2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease. Blood 83:2329-2333
13. De Silva DM, Askwith CC, Kaplan J (1996) Molecular mechanisms of iron uptake in eukaryotes. Physiol Rev 76:31-47
14. Deugnier Y, Loréal O, Turlin B, Guyader D, Jouanolle H, Moirand R, Jacquelinet C, Brissot P (1992) Liver pathology in genetic hemochromatosis: a review of 135 homozygous cases and their bioclinical correlations. Gastroenterology 102:2050-2059
15. Deugnier Y, Guyader D, Crantok L, Lopez JM, Turlin B, Yaouang J, Jouanolle H, Campion JP, Launois B, Halliday JW et al (1993) Primary liver cancer in genetic hemochromatosis: a clinical, pathological and pathogenetic study of 54 cases. Gastroenterology 1104:228-234
16. Gaboriau F, Chantrel-Groussard K, Rakba N, Loyer P, Pasdeloup N, Hider RC, Brissot P, Lescoat G (2004) Iron mobilization, cytoprotection and inhibition of cell proliferation in normal and transformed rat hepatocyte cultures by the hydroxypyridinone CP411, compared to CP20: a biological and physicochemical study. Biochem Pharmacol 67:1479-1487
17. Glickstein H, El RB, Shvartsman M, Cabantchik ZI (2005) Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood 106(9):3242-3250
18. Glickstein H, El RB, Link G, Breuer W, Konijn AM, Hershko C, Nick H, Cabantchik ZI (2006) Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood 108(9):3195-3203
19. Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I, Guyomard C, Lucas J, Trepo C, Guguen-Guillouzo C (2002) Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci USA 99(24):15655-15660
20. Huang XP, Spino M, Thiessen JJ (2006) Transport kinetics of iron chelators and their chelates in Caco-2 cells. Pharm Res 23(2):280-290
21. Kontoghiorghes GJ (1986) Iron mobilization from ferritin using alpha-oxohydroxy heteroaromatic chelators. Biochem J 233(1):299-302
22. Kontoghiorghes GJ, Evans RW (1985) Site specificity of iron removal from transferrin by alpha-ketohydroxypyridine chelators. FEBS Lett 189(1):141-144
23. Kontoghiorghes GJ, Goddard JG, Bartlett AN, Sheppard L (1990) Pharmacokinetic studies in humans with the oral iron chelator 1, 2-dimethyl-3-hydroxypyrid-4-one. Clin Pharmacol Ther 48(3):255-261
24. Kushner JP, Porter JP, Olivieri NF (2001) Secondary iron overload. Hematology/the education program of the American Society of Hematology American Society of Hematology, pp 47-61
25. Lescoat G, Chantrel-Groussard K, Pasdeloup N, Nick H, Brissot P, Gaboriau F (2007) Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism. Cell Prolif 40(5):755-767
26. Mamtani M, Kulkarni H (2008) Influence of iron chelators on myocardial iron and cardiac function in transfusiondependent thalassaemia: a systematic review and metaanalysis. Br J Haematol 141(6):882-890
27. Muckenthaler MU, Galy B, Hentze MW (2008) Systemic iron homeostasis and the iron-responsive element/iron-regulatory protein (IRE/IRP) regulatory network. Annu Rev Nutr 28:197-213
28. Olivieri NF, Koren G, Matsui D, Liu PP, Blendis L, Cameron R, McClelland RA, Templeton DM (1992) Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood 79(10):2741-2748
29. R'Zik S, Beguin Y (2001) Serum soluble transferrin receptor concentration is an accurate estimate of the mass of tissue receptors. Exp Hematol 29(6):677-685
30. Richardson DR (1997) Potential of iron chelators as effective antiproliferative agents. Can J Physiol Pharmacol 75(10-11):1164-1180
31. Richardson DR, Milnes K (1997) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II : the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. Blood 89:3025-3038
32. Rodbard D, McClean SW (1977) Automated computer analysis for enzymemultiplied immunological techniques. Clin Chem 23(1):112-115
33. Rouan MC, Marfil F, Mangoni P, Sechaud R, Humbert H, Maurer G (2001) Determination of a new oral iron chelator, ICL670, and its iron complex in plasma by highperformance liquid chromatography and ultraviolet detection. J Chromatogr B Biomed Sci Appl 755(1- 2):203-213
34. Ruhnke M, Ungefroren H, Zehle G, Bader M, Kremer B, Fandrich F (2003) Long-term culture and differentiation of rat embryonic stem cell-like cells into neuronal, glial, endothelial, and hepatic lineages. Stem cells (Dayton, Ohio) 428(4):428-436
35. Rund D, Rachmilewitz E (2005) Beta-thalassemia. N Engl J Med 353(11):1135-1146
36. Sohn YS, Breuer W, Munnich A, Cabantchik ZI (2008) Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications. Blood 111(3):1690-1699
37. Tenopoulou M, Kurz T, Doulias PT, Galaris D, Brunk UT (2007) Does the calcein-AM method assay the total cellular 'labile iron pool' or only a fraction of it? Biochem J 403(2):261-266
38. Theil EC (1987) Ferritin: structure, gene regulation, and cellular function in animals, plants, and microorganisms. Annu Rev Biochem 56:289-315
39. Troadec MB, Glaise D, Lamirault G, Le Cunff M, Guerin E, Le Meur N, Detivaud L, Zindy P, Leroyer P, Guisle I et al (2006) Hepatocyte iron loading capacity is associated with differentiation and repression of motility in the HepaRG cell line. Genomics 87(1):93-103
40. Turlin B, Deugnier Y (2002) Iron overload disorders. Clin Liver Dis 6:481-496
41. Valle P, Timeus F, Piglione M, Rosso P, di Montezemolo LC, Crescenzio N, Marranca D, Ramenghi U (1995) Effect of different exposures to desferrioxamine on neuroblastoma cell lines. Pediatr Hematol Oncol 12:439-446
42. Wright TL, Brissot P, Ma WL, Weisiger RA (1986) Characterisation of non-tranferrin-bound iron clearance by rat liver. J Biol Chem 261:10909-10914